Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
41.76 USD | +1.40% | +0.64% | -19.81% |
Kurzporträt
Die Vereinigten Staaten machen 70,1% des Nettoumsatzes aus.
Mitarbeiterzahl: 34 100
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Innovative Medicines
100,0
%
| 46 159 | 100,0 % | 45 006 | 100,0 % | -2.50% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
70,1
%
| 31 828 | 69,0 % | 31 555 | 70,1 % | -0.86% |
International
28,3
%
| 13 497 | 29,2 % | 12 752 | 28,3 % | -5.52% |
Other
1,6
%
| 834 | 1,8 % | 699 | 1,6 % | -16.19% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 53 | 01.02.15 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20.11.19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 01.01.03 | |
Chief Tech/Sci/R&D Officer | - | - | |
Samit Hirawat
CTO | Chief Tech/Sci/R&D Officer | 55 | 01.01.19 |
Robert Plenge
CTO | Chief Tech/Sci/R&D Officer | 53 | 01.11.19 |
Laura Hortas
IRO | Public Communications Contact | - | - |
Corporate Officer/Principal | - | - | |
Cari Gallman
PRN | Corporate Officer/Principal | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20.11.19 |
Peter Arduini
BRD | Director/Board Member | 59 | 01.04.16 |
Derica Rice
BRD | Director/Board Member | 59 | 01.09.20 |
Paula Price
BRD | Director/Board Member | 62 | 01.09.20 |
Theodore Samuels
BRD | Director/Board Member | 69 | 21.02.17 |
David Elkins
DFI | Director of Finance/CFO | 55 | 20.11.19 |
Chief Executive Officer | 53 | 01.02.15 | |
Julia Haller
BRD | Director/Board Member | 69 | 20.11.19 |
Deepak Bhatt
BRD | Director/Board Member | 56 | 14.06.22 |
Karen Vousden
BRD | Director/Board Member | 66 | 01.01.18 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 2 923 100 096 | 2 024 918 592 ( 69,27 %) | 896 000 000 ( 30,65 %) | 69,27 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
5 075 304 | 5,31% | 136 322 665 $ | |
759 145 | 6,36% | 19 358 198 $ | |
COMPUGEN LTD. 5,31% | 4 757 058 | 5,31% | 10 322 816 $ |
CELULARITY INC. 5,49% | 1 195 327 | 5,49% | 3 717 467 $ |
Unternehmenskontakt
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.comKonzerngesellschaften
Name | Kategorie und Branche |
---|---|
Bristol-Myers Squibb India Pvt Ltd.
Bristol-Myers Squibb India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb India Pvt Ltd. is an Indian company that discovers, develops, and delivers medicines for immuno-oncology. The company is based in Mumbai, India. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb SA (Spain)
| |
Bristol-Myers Squibb AE
| |
Swords Laboratories Unlimited Co.
Swords Laboratories Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Swords Laboratories Unlimited Co. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Swords, Ireland. |
Pharmaceuticals: Major
|
BMS Strategic Portfolio Investments Holdings, Inc.
| |
Bristol-Myers Squibb (Finland) Oy Ab
Bristol-Myers Squibb (Finland) Oy Ab Pharmaceuticals: GenericHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb (Finland) Oy Ab is a Finnish pharmaceutical manufacturing company. The company is based in Vantaa, Finland. The company was founded in 1974. Simone Böhrer has been the CEO of the company since 2020. |
Pharmaceuticals: Generic
|
Celgene Alpine Investment Co. LLC
| |
Bristol-Myers Squibb SARL
Bristol-Myers Squibb SARL Medical DistributorsDistribution Services Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France. |
Medical Distributors
|
Celgene Alpine Investment Co. III LLC
Celgene Alpine Investment Co. III LLC Financial ConglomeratesFinance Part of Bristol Myers Squibb Co., Celgene Alpine Investment Co. III LLC is an American company that provides investment services. The company is located in the US. |
Financial Conglomerates
|
Sektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+55.13% | 811 Mrd. | |
+43.62% | 640 Mrd. | |
-7.06% | 353 Mrd. | |
+18.13% | 333 Mrd. | |
+8.74% | 302 Mrd. | |
+16.30% | 246 Mrd. | |
+2.41% | 225 Mrd. | |
+12.47% | 218 Mrd. | |
+8.42% | 168 Mrd. |
- Börse
- Aktien
- 850501 Aktie
- BMY Aktie
- Unternehmen Bristol-Myers Squibb Company